Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.

Victor E. Marquez, James A. Kelley, Riad Agbaria, Tisipi Ben-Kasus, Jonathan C. Cheng, Christine B. Yoo, Peter A. Jones

Research output: Contribution to journalReview articlepeer-review

78 Scopus citations


1-(Beta-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) corresponds structurally to cytidine minus the exocyclic 4-amino group. The increased electrophilic character of its simple aglycon endows the molecule with unique biologic properties as a potent inhibitor of both cytidine deaminase and DNA cytosine methyltransferase. The latter activity makes zebularine a promising antitumor agent that is hydrolytically stable, preferentially targets cancer cells, and shows activity both in vitro and in experimental animals, even after oral administration.

Original languageEnglish
Pages (from-to)246-254
Number of pages9
JournalAnnals of the New York Academy of Sciences
StatePublished - 1 Jan 2005
Externally publishedYes

ASJC Scopus subject areas

  • Neuroscience (all)
  • Biochemistry, Genetics and Molecular Biology (all)
  • History and Philosophy of Science


Dive into the research topics of 'Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.'. Together they form a unique fingerprint.

Cite this